BeStock  
Stocks › Biotechnology › ACRS

Aclaris Therapeutics ACRS

US equityMarket cap rank #3543Biotechnology
$3.44 −$0.06 (-1.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.44 0.00%
Open$3.44
Prev close$3.50
Day range$3.40 – $3.55
Volume2.19M
Market cap$545.63M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.48M-55.1% YoY
Operating profit-$21.94M-28.7% YoY
Net profit-$18.51M-26.7% YoY
Diluted EPS-$0.12+0.0% YoY
Free cash flow-$24.09M-119.9% YoY
Operating cash flow-$24.08M

Revenue, last 8 quarters

$9.2MDec '24$1.5MMar '25$1.8MJun '25$3.3MSep '25$1.3MDec '25$2.0MMar '26$1.6MJun '26$1.5MSep '26

Net profit, last 8 quarters

$-96.6MDec '24$-15.1MMar '25$-15.4MJun '25$-14.6MSep '25$-19.8MDec '25$-19.8MMar '26$-21.5MJun '26$-18.5MSep '26

Diluted EPS by quarter

-1.01Dec '24-0.12Mar '25-0.13Jun '25-0.12Sep '25-0.16Dec '25-0.15Mar '26-0.15Jun '26-0.12Sep '26

Free cash flow by quarter

$-44.7MDec '24$-13.9MMar '25$-9.2MJun '25$-11.0MSep '25$-13.2MDec '25$-18.2MMar '26$-19.9MJun '26$-24.1MSep '26

Annual revenue

$6.5MFY20$6.8MFY21$29.8MFY22$31.2MFY23$18.7MFY24$7.8MFY25

Profitability & balance sheet

Gross margin5.8%
Operating margin-1,412.4%
Net margin-1,244.1%
Return on equity-55.5%
Return on assets-40.7%
Return on invested capital-60.2%
Current ratio5.09
Liabilities / assets22.8%
Cash & investments$114.29M
Net cash (debt)$114.29M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.48M $1.63M $2.00M $7.83M $1.30M
Total Operating Revenue $1.48M $1.63M $2.00M $7.83M $1.30M
Cost of Revenue $1.32M $1.45M $1.79M $7.28M $1.47M
Gross Profit $160,000.00 $176,000.00 $208,000.00 $542,000.00 -$174,000.00
Operating Expense $22.10M $24.11M $22.40M $74.62M $22.16M
Selling and Admin Expenses $6.04M $6.05M $6.74M $21.97M $5.58M
-General & Admin Expense $6.04M $6.05M $6.74M $21.97M $5.58M
Research & Development $16.07M $18.07M $15.66M $52.65M $16.58M
Operating Profit -$21.94M -$23.94M -$22.19M -$74.08M -$22.33M
Net Non-Operating Interest Income (Expense) $1.85M $1.76M $1.51M $7.64M $1.63M
Non-Operating Interest Income $1.85M $1.76M $1.51M $7.64M $1.63M
Other Income (Expense) $1.59M $672,000.00 $854,000.00 $1.52M $905,000.00
Special Income (Charges) $600,000.00 -$300,000.00 $0.00 -$2.30M -$400,000.00
-Less:Restructuring and Mergern & Acquisition -$600,000.00 $300,000.00 $0.00 $2.30M $400,000.00
Other Non-Operating Income (Expenses) $985,000.00 $972,000.00 $854,000.00 $3.82M $1.31M
Pretax Profit -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Net Profit -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Profit from Continuing Operations -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Net Income to Parent Company -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Net Income to Common Stockholders -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Basic EPS -$0.12 -$0.15 -$0.15 -$0.53 -$0.16
Diluted EPS -$0.12 -$0.15 -$0.15 -$0.53 -$0.16

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $216.16M $179.69M $198.72M $160.46M $160.46M
Total Current Assets $123.23M $97.77M $110.23M $96.32M $96.32M
Cash and Cash Equivalents & Short-Term Investments $114.29M $91.56M $105.42M $90.75M $90.75M
-Cash and Cash Equivalents $20.39M $19.17M $28.66M $19.96M $19.96M
-Short Term Investments $93.90M $72.39M $76.76M $70.79M $70.79M
Receivables $8.94M – – – –
-Accounts Receivable $8.94M – – – –
Total Non-Current Assets $92.93M $81.93M $88.49M $64.14M $64.14M
Net PPE $624,000.00 $664,000.00 $750,000.00 $761,000.00 $761,000.00
Investments and Advances $90.31M $79.07M $85.37M $60.61M $60.61M
-Available for Sale Securities $90.31M $79.07M $85.37M $60.61M $60.61M
Other Non-Current Assets $1.99M $2.20M $2.37M $2.77M $2.77M
Total Liabilities $49.36M $55.11M $55.07M $57.38M $57.38M
Total Current Liabilities $24.22M $28.24M $27.37M $28.65M $28.65M
Payables $9.07M $15.52M $14.73M $13.16M $13.16M
-Accounts Payable $9.07M $15.52M $14.73M $13.16M $13.16M
Current Accrued Expenses $4.32M $3.08M $3.85M $3.49M $3.49M
Current Deferred Liabilities $3.97M $3.98M $3.97M $3.94M $3.94M
Other Current Liabilities $2.81M $2.79M $2.77M $2.75M $2.75M
Total Non-Current Liabilities $25.14M $26.87M $27.70M $28.73M $28.73M
Non-Current Deferred Liabilities $13.33M $14.31M $15.29M $16.17M $16.17M
Other Non-Current Liabilities $11.80M $12.56M $12.42M $12.57M $12.57M
Total Equity $166.80M $124.58M $143.65M $103.08M $103.08M
Stockholders' Equity $166.80M $124.58M $143.65M $103.08M $103.08M
Capital Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Common Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.20B $1.13B $1.13B $1.07B $1.07B
Retained Earnings -$1.03B -$1.01B -$987.61M -$967.78M -$967.78M
Gains/Losses Not Affecting Retained Earnings -$1.12M -$304,000.00 $22,000.00 $610,000.00 $610,000.00
Other Current Assets – $6.21M $4.81M $5.57M $5.57M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$24.08M -$19.85M -$18.15M -$47.11M -$13.13M
Net cash flow from continuing operations -$24.08M -$19.85M -$18.15M -$47.11M -$13.13M
Net Income from Continuing Operations -$18.51M -$21.51M -$19.82M -$64.92M -$19.80M
Depreciation & Depletion & Amortization $100,000.00 $107,000.00 $102,000.00 $454,000.00 $102,000.00
Other Non-Cash Items -$600,000.00 – – $2.30M $400,000.00
Change in Working Capital -$8.09M -$1.42M -$1.63M $2.67M $3.24M
-Change in Prepaid Assets -$2.91M – – $6.14M -$672,000.00
-Change in Payables and Accrued Expense -$4.20M $770,000.00 -$1.51M $350,000.00 $5.21M
-Change In Other Working Capital -$985,000.00 -$972,000.00 -$854,000.00 -$3.82M -$1.31M
Net cash flow from investing -$33.22M $10.26M -$30.93M $48.37M $10.37M
Net Cash Flow from Continuing Investing Activities -$33.22M $10.26M -$30.93M $48.37M $10.37M
Net PPE Purchase and Sale -$13,000.00 -$58,000.00 -$13,000.00 -$111,000.00 -$24,000.00
Net Business Purchase and Sale $0.00 – – -$833,000.00 $0.00
Net Investment Purchase and Sale -$33.21M $10.32M -$30.92M $49.31M $10.39M
Financing Cash Flow $58.53M $91,000.00 $57.78M -$5.86M -$2.53M
Net Cash Flow from Continuing Financing Activities $58.53M $91,000.00 $57.78M -$5.86M -$2.53M
Net Common Stock Issuance $58.37M $0.00 $57.88M $0.00 $0.00
Proceeds from Stock Option Exercised $223,000.00 $114,000.00 $151,000.00 $0.00 $0.00
Net Other Financing Charges -$63,000.00 -$23,000.00 -$250,000.00 -$5.86M -$2.53M
Ending Cash Balance $20.39M $19.17M $28.66M $19.96M $19.96M
Net Change in Cash $1.23M -$9.49M $8.70M -$4.61M -$5.30M
Beginning Cash Balance $19.17M $28.66M $19.96M $24.57M $25.26M
Free Cash Flow -$24.09M -$19.91M -$18.16M -$47.22M -$13.16M
-Change in Receivables – – $742,000.00 – –
Net Intangibles Purchase and Sale – – $0.00 $0.00 –

Discussion

No comments yet — be the first to weigh in on ACRS.

Sign in to join the discussion.

Scroll to Top